Kazia Therapeutics Limited

About Kazia Therapeutics Limited

Kazia Therapeutics Limited is a biopharmaceutical company focused on developing innovative drug candidates to treat challenging cancers such as brain, renal, and liver cancer, which are underserved by current therapies. Their mission is to help patients and clinicians confront the most difficult cancers in modern medicine by identifying and developing promising drug candidates through global collaboration with leading cancer treatment experts.

Products & Services

Paxalisib:A drug candidate being tested in clinical trials for various cancers, including brain cancer, breast cancer, and potentially Parkinson's disease, with recent data showing efficacy in reducing circulating tumor cells in triple-negative breast cancer patients.

EVT801:A drug candidate in Phase 1 clinical trials for advanced cancer patients, with successful completion of stage 1 reported.

Specialties

Oncology drug development Brain cancer treatment Breast cancer treatment Clinical trials for advanced cancers Collaboration with global cancer research experts

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement of Equity Securities (PIPE) T: - FT: Private Placement of Equity Securities (PIPE)	A: 50000000 MR: - FA: $50.0 million FAN: 50000000	D: 2025-12-02 FD: 2025-12-02	6 investors
2	RT: Private Placement (PIPE) T: - FT: Private Placement (PIPE)	A: 2000000 MR: - FA: $2.0 million FAN: 2000000	D: 2025-08-01 FD: 2025-08-01	1 investors
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2000000 MR: - FA: approximately $2.0 million FAN: 2000000	D: 2025-01-14 FD: 2025-01-14	1 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2000000 MR: - FA: approximately $2.0 million FAN: 2000000	D: 2025-01-10 FD: 2025-01-10	-
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2000000 MR: - FA: $2 million FAN: 2000000	D: 2023-12-05 FD: 2023-12-05	1 investors
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2000000 MR: - FA: approximately $2 million FAN: 2000000	D: 2023-12-01 FD: 2023-12-01	1 investors
7	RT: Placement T: - FT: Placement	A: 4500000 MR: - FA: A$4.5 million FAN: 4500000	D: 2023-01-16 FD: 2023-01-16	1 investors

Private Placement of Equity Securities (PIPE) Latest

2025-12-02

$50.0M

6 investors (Pro only)

Private Placement (PIPE) 2025-08-01

$2.0M

Registered Direct Offering 2025-01-14

$2.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

John Friend

Chief Executive Officer

J

Jeffrey Bonacorda

VP Finance and Controller

E

Elissa Hansen

Company Secretary

P

Priscilla Brastianos

Director of the Central Nervous System Metastasis Center

J

John de Groot

Division Chief of the Neuro-Oncology Division

A

Alan Olivero

Consultant specializing in drug discovery and development

View 9 more team members with Pro

Unlock Full Team Directory

Recent News